John Thomas

Dundee, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Structure-activity relationships of 1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-diones as inhibitors of Trypanosoma cruzi.

Structure-activity relationships of 1,5-dihydro-2H-benzo[b][1,4]diazepine-2,4(3H)-diones as inhibitors of Trypanosoma cruzi.

Journal: RSC medicinal chemistry

Published: February 28, 2025

Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors.

Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors.

Journal: The Journal of biological chemistry

Published: May 22, 2024

Short-course combination treatment for experimental chronic Chagas disease.

Short-course combination treatment for experimental chronic Chagas disease.

Journal: Science translational medicine

Published: December 13, 2023

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 28, 2023

Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity.

Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity.

Journal: PLoS neglected tropical diseases

Published: July 27, 2023

Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.

Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.

Journal: European journal of medicinal chemistry

Published: February 15, 2022

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

Journal: Journal of medicinal chemistry

Published: April 27, 2021

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity.

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity.

Journal: Journal of medicinal chemistry

Published: July 15, 2020

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis.

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis.

Journal: RSC medicinal chemistry

Published: June 12, 2020

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 10, 2019

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.

Journal: Journal of medicinal chemistry

Published: December 21, 2018

2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease.

2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease.

Journal: Bioorganic & medicinal chemistry letters

Published: June 05, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026